Aurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 18.9%, EPS grew 81.3%, free cash flow grew 19.1% and total debt fell 25.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow AUPH
Aurinia Pharmaceuticals Inc (AUPH) P/E ratio
As of 16 October 2026, Aurinia Pharmaceuticals Inc (AUPH) trades at a P/E ratio of 6.9×. Over the past ten years it has ranged from 0.0× (December 2024) to 200× (December 2024); the current reading is higher than 89% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 7.4× | (96.32%) |
| FY2024 | 200× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 7.1× | 8.28% |
| Mar 2026 | 6.6× | (10.78%) |
| Dec 2025 | 7.4× | (61.42%) |
| Sep 2025 | 19.1× | (1.03%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NVAX Novavax, Inc. compare | n/m |
| IRON Disc Medicine, Inc. compare | n/m |
| VRDN Viridian Therapeutics, Inc. compare | n/m |
| SLS SELLAS Life Sciences Group, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | n/m |
| RXRX Recursion Pharmaceuticals, Inc. compare | n/m |
| CLDX Celldex Therapeutics, Inc. compare | n/m |
| AUPH Aurinia Pharmaceuticals Inc | 6.9× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 12.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)